Speratum is a medical research venture launching a first-of its class, patented treatment for pancreatic cancer while developing breakthrough microRNA-based therapies to treat and diagnose other malignancies. 



Pancreatic adenocarcinoma is the deadliest of cancers. Due to its aggressive nature and innate resistance to chemotherapy, developing new treatments for pancreatic cancer has been a losing battle. There are currently no effective treatments for this disease, which has an incidence of ~300,000 new cases annually; 80% of these newly diagnosed patients will succumb to the cancer in less than one year. In fact, only 5% of those affected survive for 5 years.